-
Company Insights
Innovation and Patenting activity of Wockhardt Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Wockhardt Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Levonadifloxacin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levonadifloxacin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levonadifloxacin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Levonadifloxacin in Gram-Negative Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levonadifloxacin in Gram-Negative Bacterial Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levonadifloxacin in Gram-Negative Bacterial Infections Drug Details: Levonadifloxacin (Emrok) is a...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Methicillin-Resistant Staphylococcus Aureus (MRSA) Clinical Trial Report Overview A total of 418 MRSA clinical trials were conducted as of January 2024. The MRSA clinical trial report provides a comprehensive understanding of the MRSA clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       ...
-
Product Insights
Community-Acquired Bacterial Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Community-Acquired Bacterial Pneumonia - Drugs In Development, 2023’, provides an overview of the Community-Acquired Bacterial Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community-Acquired Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2023’, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Pyelonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pyelonephritis - Drugs In Development, 2023’, provides an overview of the Pyelonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2023’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Drugs In Development, 2023’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Community Acquired Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Community Acquired Pneumonia - Drugs In Development, 2023’, provides an overview of the Community Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...